7 Biotechs With Catalysts in the Next Month
Here, 24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the rest of September and in October.
All Work
Chris Lange
CloudFlare Enters the Market With a Bang
CloudFlare entered the market with a bang on Friday. Shares went out at $19.53, well above the announced $15 per share.
Why Analysts Are Sidelined on Oracle After Earnings
When Oracle released fiscal first-quarter financial results after markets closed Wednesday, overall the report was not received well. Analysts were quick to weigh in on the results.
Why This Analyst Sees 20% Upside at Etsy From New Initiatives
Wedbush upgraded Etsy and raised its price target on the shares, citing a critical mass of new initiatives.
FDA Gets Off the Pot for IBS Treatment Approval
Ardelyx shares dropped on Friday after the firm announced that the FDA has approved its treatment of irritable bowel syndrome with constipation in adults.
Are Broadcom Earnings Enough?
Broadcom released its fiscal third quarter financial results after the markets closed on Thursday. The firm said that it had $5.16 in earnings per share (EPS) and $5.515 billion in revenue, compared with consensus…
Are Millennials Good Tippers?
Proper etiquette would suggest tipping for certain services, but this isn’t always the case. Some people are more generous than others, while many aren’t giving tips at all.
SmileDirectClub Fails to Impress in IPO
SmileDirectClub shares dropped on Thursday after its initial public offering.
10X Genomics Enters the Market With a Bang
Life science technology company 10X Genomics entered the market with a bang on Thursday in its initial public offering.
Does This Macular Degeneration Study Deserve More Credit?
Adverum Bio shares dropped sharply on Thursday after the firm announced data from its Optic Phase 1 clinical trial in wet age-related macular degeneration.
What to Expect When Broadcom Reports After the Close
Broadcom is scheduled to release its fiscal third-quarter financial results after the markets close on Thursday, and analysts are looking for growth on the top and bottom lines.
Major Biotechs Scare Off Short Sellers
The August 30 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Short Sellers Can’t Make Up Their Minds on Big Pharma
The August 30 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks was mixed.
Does Semiconductor Short Interest Hint at New Market Highs?
The August 30 short interest data have been compared with the previous report. Short interest in most of these selected semiconductor stocks decreased.
Should Oracle Be Worried After This Quarter?
Oracle released its fiscal first quarter financial results after the markets closed on Wednesday. The firm said that it had $0.81 in earnings per share (EPS) and $9.2 billion in revenue, compared with consensus…
What’s Left After Lexicon’s Terminated Partnership With Sanofi
After Lexicon Pharmaceuticals announced the termination of its alliance with Sanofi, its shares rallied on Wednesday.
What to Watch When Oracle Releases Earnings
Oracle is set to report its fiscal first-quarter financial results after the markets close on Thursday. Analysts are looking for solid year-on-year earnings growth.
Millennials Are Facing More Problems Buying Houses
Across the country, rapid home-price growth and low inventories of affordable housing have been making it harder for prospective homebuyers, especially millennials.
What to Expect When Kroger Reports Thursday Morning
Kroger is scheduled to release its fiscal second-quarter financial results before the markets open on Thursday. Wall Street is looking for similar results to last year.
What’s Pulling Dave & Buster’s Down
Dave & Buster’s retreated early Wednesday after it reported its fiscal second-quarter financial results late on Tuesday.